Small biosensors
- large opportunities in medicine
Early warning – Early action
Alertis Medical AS is a medical device company with a new and
unique technology for biosensors that will help save patients
health and lives by providing early warning about critical
changes in blood perfusion and respiration. The miniaturized
biosensors are easy to use and will save health care expenses.
The technology of miniaturized biosensors addresses a considerable
need in modern medicine by providing early warning of life
threatening conditions, by measuring tissue pCO2, real time, on-line, as an indicator of adequate tissue oxygenation. There are no reliable, cost effective
and user friendly methods available for this purpose today. Alertis unique biosensor technology will enable early warning
and thereby early intervention of critical conditions related to changes in
blood flow and respiration, providing a new tool for reducing
mortality and morbidity as well as medical expenses.
This is a universal monitoring tool in modern medicine, with
numerous potential applications which are about to be explored.
Some key clinical areas for the biosensors will primarily be post
operative monitoring for the first 2-5 days following:
·
Orthopaedic surgery
·
Plastic surgery
·
Cardiac surgery
·
Vascular surgery
·
Solid Organ Transplantation
and general monitoring to detect critical conditions such as:
·
Sepsis
·
Shock
·
ARDS (Acute Respiratory Distress Syndrome
The total market potential for the biosensor portfolio is estimated
to more than € 2 billion. The sensors can be produced at low
cost and will provide excellent health economy for the users.
Alertis’ development strategy is focused key indications with
documented clinical need. The company has obtained market
clearance by the CE mark for the EU market and FDA clearance
(510(k)) for
USA
for its first biosensor product IscAlert™.
The company works closely with the Interventional Centre at
Rikshospitalet-Radiumhospitalet (the National Hospital, where
the inventors are working) where significant R&D activities are
carried out. |